Comparative Pharmacology
Head-to-head clinical analysis: ELFABRIO versus KOGLUCOID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ELFABRIO versus KOGLUCOID.
ELFABRIO vs KOGLUCOID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Recombinant human α-galactosidase A enzyme that hydrolyzes globotriaosylceramide (Gb3) and other glycosphingolipids with terminal α-galactosyl groups, thereby reducing accumulation in tissues.
KOGLUCOID (velaglucerase alfa) is a recombinant form of human glucocerebrosidase, which catalyzes the hydrolysis of glucocerebroside to glucose and ceramide. It replaces the deficient enzyme in patients with Gaucher disease, reducing accumulation of glucocerebroside in macrophages.
1 mg/kg intravenously over 2 hours every 2 weeks.
60 U/kg intravenously over 4 hours every 2 weeks.
None Documented
None Documented
Terminal elimination half-life approximately 0.5–1 hour; short half-life necessitates twice-weekly intravenous dosing.
Terminal elimination half-life is approximately 15-30 minutes (range 11-35 min) in plasma after IV infusion. Short half-life necessitates frequent dosing (every 2 weeks). This reflects rapid clearance via receptor-mediated uptake into macrophages.
Primarily eliminated via renal excretion as intact protein; minimal biliary/fecal elimination (<1%).
KOGLUCOID (velaglucerase alfa) is a recombinant human glucocerebrosidase used for Gaucher disease. It is a protein therapeutic; elimination occurs via catabolism (proteolysis) to small peptides and amino acids. No significant renal or biliary excretion of intact drug. <1% excreted unchanged in urine.
Category C
Category C
Enzyme Replacement Therapy
Enzyme Replacement Therapy